A complete application in a minute
Tailored resume and cover letter, ready to send.
The CHUM Microbiome Centre invites an experienced Clinical Research Associate (CRA) to join a team pioneering microbiome-based therapies to improve cancer treatment outcomes. You will lead regulatory submissions, study start-up, and multicentre coordination across Canada, with emphasis on Health Canada regulations and ICH-GCP.
The successful candidate will develop and implement multicentre Canadian trials investigating microbiome-based strategies to enhance cancer immunotherapy, coordinate site
The CHUM Microbiome Centre, co-directed by Dr. Arielle Elkrief and Dr. Bertrand Routy, isseeking an experienced and highly motivated Clinical Research Associate (CRA)to joinour team pioneering microbiome-basedtherapies to improve cancer treatment outcomes.
Our research program is internationally recognized for developing innovative strategies to harness the gut microbiome to improve responses to cancer immunotherapy, including fecal microbiota transplantation (FMT), prebiotic interventions such as camu-camu, and dietary interventions. Our work spans scientific discovery, translational research, and early- to late-phase clinical trials.
The successful candidate will play a central role in the development and implementation of a multicentre Canadian clinical trial investigating novel microbiome-based strategies to enhance the efficacy of cancer immunotherapy.
Join the CHUM Microbiome Centre, a world-leading centre in microbiome and cancer research, and help advancea new generation ofcancer treatments targetingthe gut microbiome.
Our team has pioneered clinical trials evaluating FMT, prebiotics, and nutritional interventions to improve immunotherapy outcomes. We are now translating these discoveries into new microbiome-based therapeutic strategies with the potential to change how cancer is treated.
This position offers the opportunity to work directly withinternationally recognized clinician-scientists,collaborate with leading cancer centres across Canada, and takea central role in bringingan innovative therapy from clinical trial development to patients.